课题基金 / 基金详情

New T Cell Coinhibitory Pathway and Type 1 Diabetes

New T Cell Coinhibitory Pathway and Type 1 Diabetes
新的 T 细胞共抑制途径与 1 型糖尿病
批准号:
8000981
负责人:
Xingxing Zang
金额:
$9.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-12-21 至 2010-02-28

项目摘要

项目成果

Xingxing Zang的其他基金

相似基金

相关文献

中文摘要
翻译
免疫学 T淋巴细胞是获得性免疫的中心介质,在免疫系统中起着关键作用。 在适当的免疫应答(如针对 病原体)和异常的(如自身免疫反应,导致类型 1例糖尿病)。最佳活化、增殖和分化为效应子 T细胞的功能需要同时发生两种信号:抗原 通过T细胞抗原受体的特异性信号,以及额外的共刺激信号 (共刺激)主要由B7和CD 28之间的相互作用产生 家庭为了理解B7-1的T细胞共刺激, 在过去的十年中,B7-2/CD 28,CTLA-4通路塑造了我们的大部分 了解免疫系统和免疫相关疾病, 1型糖尿病我们发现了B7家族的最新成员 B7 x,其能够在体外抑制T细胞功能(共抑制)。然而,在这方面, B7 x在糖尿病中的作用尚不清楚。有趣的是,我们最近发现, 与B7-1和B7-2不同,人类和小鼠B7 x基因都位于胰岛素中, 依赖性糖尿病基因座,并在胰岛中表达。而且我们 他们发现,在胰腺细胞中过度表达B7 x的转基因小鼠, 抗CD 4 T细胞介导的1型糖尿病。根据初步数据, 我们假设B7 x代表了一种新的T细胞共抑制途径, 减弱胰腺中的效应T细胞功能。我们得到了一个数字 重要工具(针对B7 x的mAb、B7 x转基因小鼠、B7 x敲除小鼠等) 这为我们提供了独特的机会来分析B7 x通路在 1型糖尿病总的来说,这个项目的研究不仅可以促进我们的 了解1型糖尿病的致病过程及其 并发症,并导致临床治疗的合理方法 干预
英文摘要
Immunology T lymphocytes are central mediators of adaptive immunity, playing a key role in both appropriate immune responses (such as immunity against pathogens) and abnormal ones (such as autoimmune response that lead to type 1 diabetes). Optimal activation, proliferation, and differentiation to effector function of T cells require a simultaneous occurrence of two signals: antigen specific signals via T cell antigen receptors, and additional costimulatory signals (costimulation) generated mainly by the interaction between the B7 and CD28 families. The intense effort towards understanding T cell costimulation of B7-1, B7-2/CD28, CTLA-4 pathway over the past decade has shaped much of our understanding regarding the immune system and immune-related diseases such as type 1 diabetes. We have discovered the newest member of the B7 family, B7x, which is capable of inhibiting T cell function in vitro (coinhibition). However, the role of B7x in diabetes is unknown. Interestingly, we have recently found that, unlike B7-1 and B7-2, both human and mouse B7x genes are located in insulin- dependent diabetes loci and are expressed in pancreatic islets. Moreover, we have found that transgenic mice overexpressing B7x in pancreatic ¿ cells are resistant to CD4 T cell mediated type 1 diabetes. Based on the preliminary data, we have hypothesized that B7x represents a novel T cell coinhibitory pathway that attenuates effector T cell function in pancreas. We have generated a number of important tools (mAbs to B7x, B7x transgenic mice, B7x knock-out mice, etc.) that provide us with unique opportunities to analyze the role of B7x pathway in type 1 diabetes. Overall, the studies of this project may not only advance our understanding of the pathogenic processes underlying type 1 diabetes and its complicatios but also lead to a rational approach for clinical therapeutic intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A New Immune Checkpoint Pathway in Human Bladder Cancer
A new immune checkpoint pathway in human bladder cancer
Mechanisms and Therapies of B7x and B7-H3 in T1D
Mechanisms and therapies of B7x and B7-H3 in T1D
海外基金